 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
2003Andreassen OA, Ferrante RJ, Aamo TO, Bean MF, Jorgensen HA. Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats. Neuroscience 2003; 122:717-725. [PubMed] Bachman DL, Green RC, Benke KS, Cupples LA, Farrer LA. Comparison of Alzheimer’s disease risk factors in white and African American families. Neurology 2003; 60:1372-1374. [PubMed] Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington’s disease transgenic mice. Intl Society for Neurochem 2003; 85:1359-1367. [PubMed] Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, Hersch SM. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington’s disease mice. Journal of Neuroscience 2003; 23:9418-9427. [PubMed] Ganzini L, Volicer L, Nelson W, Derse A. Pitfalls in assessment of decision-making capacity. Psychosomatics 2003; 44:237-243. [PubMed] Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, Kukull WA, Chui H, Edeki T, Griffith PA, Friedland RP, Bachman D, Farrer L. Depression as a risk factor for Alzheimer disease: the MIRAGE study. Archives of Neurology 2003; 60:753-759. [PDF] Hipps YG, Roberts JS, Farrer LA, Green RC. Differences between African Americans and whites in their attitudes toward genetic testing for Alzheimer’s disease. Genetic Testing 2003; 7:39-44. [PubMed] Roberts JS, LaRusse SA, Katzen H, Whitehouse PJ, Barber M, Post SG, Relkin N, Quaid K, Pietrzak RH, Cupples LA, Farrer LA, Brown T, Green RC. Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Disease and Associated Disorders 2003; 17:86-93. [PDF] Roberts JS, Connell CM, Cisewski D, Hipps YG, Demissie S, Green RC. Differences between African Americans and Whites in their perceptions of Alzheimer disease. Alzheimer Disease and Associated Disorders 2003;17:19-26. [PubMed] Sheridan PL, Solomont J, Kowall N, Hausdorff JM. Influence of executive function on locomotor function: divided attention increases gait variability in Alzheimer’s disease. JAGS 2003; 51:1633-1637. [PubMed] Volicer L, Hurley AC. Management of behavioral symptoms in progressive degenerative dementias. Journal of Gerontology 2003; 58A:837-845. [PubMed] Volicer L, Hurley AC, Blasi ZV. Characteristics of dementia end-of-life care across care settings. American Journal of Hospice & Palliative Care 2003; 20:191-200. [PubMed] Wan X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, Ferrante RJ, Kristal BS, Friedlander RM. Minocycline inhibits caspase-independent and dependent mitochondrial cell death pathways in models of Huntington’s disease. PNAS 2003; 100:10483-10487. [PubMed] Warden V, Hurley AC, Volicer L. Development and psychometric evaluation of the pain assessment in advanced dementia (PAINAD) scale. Journal of the American Medical Directors Association 2003; 4:9-15. [PubMed] |
|
 |
 |
 |
 |
 |
|